To support BOPA members managing the introduction of biosimilar rituximab, a paper has been published on the members documents section of website which BOPA members can use in their own hospital to support rapid infusion of biosimilar rituximab
There is also details of an accompanying audit.
See http://www.bopawebsite.org/publications/members-documents
Expressions of interest for Expert Panel Sub Group to support the approval and implementation of Standardised Product Specifications The Infusions and Special Medicines Programme is inviting expressions of interest for…
Are you an oncology or haematology pharmacist with around five or more years of experience — whether Band 7 or Band 8 — and ready to take the next step…
One week left to cast your vote for the BOPA Executive Committee Election. Have your say at BOPA’s future. In 2026 we received 9 nominations for 6 positions. -Standard…
We are pleased to jointly publish the new UK multidisciplinary consensus document, Safe Management of Hazardous Medicinal Products in UK Healthcare Settings. Hazardous medicinal products (HMPs) are used across a…
The 29th BOPA Annual Conference in 2026 will be held at the ICC London Olympia on 2-4 October 2026.
Check out the latest information here: Latest Conference 2026 – BOPA
Everything you need to know
